Regenerative medicine keeps moving beyond needles and injections. One of the newer categories showing up in performance and recovery-focused clinics is topical, cell-derived body care built around material that mesenchymal stem cells release, rather than the cells themselves. NuvoCell is one such product, and it is now available through Advanced Manual Therapies.
This post walks through what NuvoCell actually is, what the broader research on this category does and does not establish, how the product is used, and what to know before trying it.
What Is NuvoCell?
NuvoCell is a topical, dual-phase (AM/PM) cream formulated by NuvoCell Biologics, a company that launched the product in 2025 for distribution through licensed healthcare providers (NuvoCell Biologics).
Despite the common shorthand “stem cell cream,” NuvoCell does not contain live stem cells. It is a cell-free formulation built around bioactive molecules and extracellular vesicles, including exosomes, that mesenchymal stem cells naturally release. NuvoCell sources this material from donated umbilical cord Wharton’s jelly tissue, then encapsulates it in lipid nanoparticles intended to help it move through the skin (NuvoCell Biologics, Regenerative Medicine).
The formula also includes camphor and a low concentration of dimethyl sulfoxide (DMSO), both established topical penetration enhancers, to help the vesicle-rich solution move past the skin’s surface layer.
The Science Behind Stem-Cell-Derived Exosomes
Using the material a stem cell releases, instead of transplanting the cell itself, has real scientific grounding, though most of that grounding comes from research on other extracellular-vesicle products and delivery routes, not from NuvoCell specifically.
A widely cited review on mesenchymal stem cell (MSC) derived extracellular vesicles describes them as carriers of proteins, lipids, messenger RNA, and non-coding RNA that reproduce many of the trophic, anti-inflammatory, anti-apoptotic, and pro-regenerative effects associated with the parent cells, without transplanting living cells. Several preclinical studies cited in that review focused specifically on joint tissue, finding that MSC-derived vesicles protected cartilage, reduced chondrocyte cell death, and calmed the immune activation that drives osteoarthritis progression (Yuan, Zhang & Chen, 2019).
A separate review focused on osteoarthritis found that MSC-derived exosomes promoted cartilage cell proliferation and migration, reduced inflammatory signaling, and helped restore the balance of cartilage-supporting proteins. That review also references a completed clinical trial in which an injectable bone-marrow-derived exosome product significantly reduced pain and improved joint function six months after a single injection (Dordevic, 2020, as summarized in a 2024 review).
It is important to be precise about what this evidence does and does not cover. Those studies used injected exosome products, not a topical cream, and none of them tested NuvoCell. The research supports that MSC-derived extracellular vesicles are biologically active and worth studying for joint and soft-tissue support. On its own, it does not establish that a topical version delivers the same effect at the skin, muscle, or joint level.
On the delivery side, DMSO has long been studied as a penetration enhancer that helps both water-soluble and fat-soluble compounds move through skin layers (Marren, 2011), and lipid-based nanocarriers have been shown in dermatology research to improve skin penetration through smaller particle size, occlusion, and controlled release (Akombaetwa et al., 2023). Those mechanisms are part of why a topical delivery approach is plausible, but plausible is not the same as proven for this specific formulation.
How NuvoCell Is Used
NuvoCell is applied topically, not injected. The standard protocol is two pumps in the morning and two pumps at night, directly over the target area, supplied as a 30-day kit. Because it does not require needles, providers can apply it, or teach patients to apply it at home, without the downtime or discomfort associated with injections.
Providers most often use NuvoCell over joints and soft tissue prone to overuse or age-related wear, including the neck, shoulders, low back, hips, knees, ankles, elbows, wrists, hands, and feet.
What the Company’s Own Pilot Data Shows
NuvoCell Biologics has published results from an internal 30-day observational pilot study involving 80 participants with chronic joint discomfort, including chronic low back pain and osteoarthritis. Participants self-reported an average 51 percent reduction in pain scores over the study period, with no adverse effects reported by the company (NuvoCell Biologics pilot study summary).
It is worth being direct about what this is and is not. It is an observational, self-reported pilot study run by the manufacturer, not an independent, randomized, placebo-controlled clinical trial. NuvoCell Biologics states this plainly in its own materials: results are observational and may vary, and the product is not intended to diagnose, treat, cure, or prevent any disease (NuvoCell Biologics, Patient Information). No exosome-based product currently holds FDA approval for joint pain or any other indication, and we think patients deserve that context up front rather than an oversold pitch.
Who NuvoCell May Help
Based on how the product is marketed and used in provider settings, NuvoCell is most often considered for adults dealing with age-related joint stiffness, overuse-related soft-tissue discomfort, or recovery support around a specific joint or region, typically alongside, not instead of, an active treatment plan such as physical therapy, shockwave therapy, or manual therapy.
Precautions and Who Should Be Careful
NuvoCell is intended for external use only. It should not be applied to open wounds, cuts, or burns, and it should not be used during pregnancy or while breastfeeding. Because the formula includes DMSO and camphor, anyone with a known sensitivity to those ingredients should discuss alternatives with their provider before starting.
The product must also be kept refrigerated and is formulated to remain stable below roughly 100°F, with providers generally storing and handling it below 80°F as a safety buffer.
As with any regenerative or biologic-adjacent product, we encourage patients to ask questions, read the manufacturer’s disclosures, and treat marketing claims, including ours, with healthy skepticism until more independent research exists.
NuvoCell at Advanced Manual Therapies
NuvoCell is now available at Advanced Manual Therapies. We are introducing it as one option among several for patients dealing with chronic joint or soft-tissue discomfort, often paired with our existing shockwave therapy, dry needling, or manual therapy plans rather than used in isolation.
If you are curious whether NuvoCell fits your situation, talk with your provider at your next visit or reach out to our team.
The Bottom Line
NuvoCell is a real example of a fast-growing category: topical products built from stem-cell-derived material. The direct clinical evidence for the cream itself is still early and company-generated. The underlying science on MSC-derived extracellular vesicles for joint and soft-tissue support is genuinely promising in preclinical and injectable studies, and the delivery science behind topical penetration enhancers is well established. What is not yet proven is that this specific topical formulation reproduces those effects at the same level.
We think that is exactly the kind of thing worth discussing honestly with your provider, which is why we are offering it as one option within a broader, personalized care plan rather than a stand-alone miracle cure.